FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This study will include patients with invasive cervical cancer that wish to keep their
fertility as much as possible in the future after treatment.
Patients who receive surgery alone may experience long-term side effects including
infertility. The purpose of this research study is to determine whether giving neo-adjuvant
chemotherapy prior to surgery can maintain fertility in patients with invasive cervical
cancer.
The neo-adjuvant chemotherapy will consist of a platinum-based chemotherapy drug cisplatin or
carboplatin, with a chemotherapy drug called paclitaxel. These are common chemotherapy drugs
used in the treatment of women with cervical cancers.
Phase:
N/A
Details
Lead Sponsor:
University Health Network, Toronto
Collaborators:
Hotel Dieu Hospital The Netherlands Cancer Institute